Innovent Biologics, Inc.
IVBXF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $126 | $55 | $56 | $55 |
| - Cash | $10 | $8 | $8 | $10 |
| + Debt | $3 | $3 | $3 | $4 |
| Enterprise Value | $120 | $50 | $51 | $49 |
| Revenue | $6 | $5 | $4 | $4 |
| % Growth | 8.8% | 38.4% | 12.8% | – |
| Gross Profit | $5 | $4 | $3 | $2 |
| % Margin | 77.3% | 75.9% | 72.3% | 70.7% |
| EBITDA | $1 | -$0 | -$0 | -$1 |
| % Margin | 17.3% | -4.2% | -6.3% | -21.2% |
| Net Income | $1 | $0 | -$0 | -$1 |
| % Margin | 14% | 5.4% | -9.9% | -25.4% |
| EPS Diluted | 0.49 | 0.18 | -0.24 | -0.56 |
| % Growth | 172.2% | 175% | 57.1% | – |
| Operating Cash Flow | $0 | $2 | -$0 | $1 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$1 |
| Free Cash Flow | $0 | $1 | -$1 | $0 |